Peer-influenced content. Sources you trust. No registration required. This is HCN.

Annals of Internal MedicineCannabis-Based Products for Chronic Pain

The review, which we covered previously, concluded that “oral, synthetic cannabis products with high THC-to-CBD ratios and sublingual, extracted cannabis products with comparable THC-to-CBD ratios may be associated with short-term improvements in chronic pain and increased risk for dizziness and sedation.”